Summary & Overview
CPT 0529U: Genomic Risk Assessment for Venous Thromboembolism
CPT code 0529U identifies a Proprietary Laboratory Analyses test — the Lifetime Genomics Risk Assessment, VTE, developed by GenomicMD Inc. The assay performs genome‑wide single‑nucleotide polymorphism analysis with focused evaluation of the F2 and F5 genes, including the Leiden variant, to estimate an individual’s genetic risk for venous thromboembolism. As a PLA code, 0529U applies only to this single manufacturer‑specific test, which has implications for coding consistency, billing transparency, and payer coverage decisions nationally.
Key payers in scope include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise summary of clinical purpose and service context, payer coverage considerations, and typical service and site‑of‑service information relevant to billing and coding teams. The publication outlines benchmarks and policy updates where available, clarifies the test’s clinical role in VTE risk assessment, and highlights administrative considerations tied to PLA coding. Data not available in the input is noted where applicable.
Billing Code Overview
CPT code 0529U is a Proprietary Laboratory Analyses (PLA) code that applies only to a single, unique laboratory test. Report 0529U only for the Lifetime Genomics Risk Assessment, VTE, from GenomicMD Inc. The test analyzes genome‑wide single‑nucleotide polymorphisms and includes targeted analysis of the F2 and F5 genes, including the Leiden variant, to determine an individual’s genetic risk of venous thromboembolism (VTE).
Service type: Genetic risk assessment using genome‑wide SNP analysis with targeted gene variant evaluation
Typical site of service: Clinical laboratory or specialized molecular diagnostics laboratory
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a personal or family history suggestive of inherited thrombophilia or a patient being evaluated for lifetime risk of venous thromboembolism (VTE). A primary care physician, hematologist, or genetic counselor orders the test 0529U (Lifetime Genomics Risk Assessment, VTE, GenomicMD Inc.) to assess genome-wide single-nucleotide polymorphisms and specific variants in the F2 and F5 genes including the Leiden variant. The clinical workflow: the provider documents indication and obtains informed consent for genetic testing; a blood or saliva specimen is collected in an outpatient clinic, phlebotomy lab, or genetic testing facility; the specimen is shipped to the performing laboratory; the laboratory performs genotyping and proprietary analysis; results are reported to the ordering provider with an interpretation of genetic risk; the provider integrates results into lifetime risk assessment, counseling, and management planning. Typical sites of service include outpatient physician offices, ambulatory phlebotomy centers, genetic counseling clinics, and commercial laboratory locations.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when the laboratory or professional service requires substantially greater effort or resources than usual for test interpretation or reporting, and documentation supports unusual complexity. |